DEFR14C: Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing
Definitive Information Statement
Elevai Labs Inc. will implement a reverse stock split, ranging from 1:2 to 1:200, to boost its stock price and maintain its Nasdaq listing.
Summary
- Elevai Labs Inc. is implementing a reverse stock split of its common stock.
- The reverse stock split ratio will range from 1:2 to 1:200, determined by the Board of Directors.
- The primary reason for the reverse stock split is to maintain the company's listing on the Nasdaq Capital Market.
- The company received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
- The reverse stock split aims to increase the per-share trading price of the common stock.
- The action was approved by written consent of majority shareholders holding approximately 56.43% of the voting power.
- The reverse stock split will not be implemented until at least 20 days after the information statement is mailed to shareholders, which is scheduled for September 5, 2024.
- The total number of authorized shares of Common Stock will remain at 300,000,000 (or 2,000,000,000 after the filing of the Certificate of Amendment).
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the delisting notice and the need for a reverse stock split, although the company is taking steps to address the issue. The success of the reverse stock split is uncertain.
Positives
- The reverse stock split aims to maintain the Nasdaq listing, which is crucial for investor confidence and access to capital.
- An increased stock price may improve marketability and liquidity of the common stock.
- The potential increase in stock price may reduce the risk of market manipulation.
- The reverse stock split is expected to increase the number of authorized, but unissued and unreserved, shares of common stock, providing flexibility for raising capital and other corporate purposes.
Negatives
- The company received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement.
- The effect of a reverse stock split on the stock price cannot be predicted with certainty.
- The stock price after a reverse stock split may not increase proportionally, potentially reducing overall market capitalization.
- The reverse stock split may decrease the liquidity of the common stock and result in higher transaction costs.
- The implementation of a reverse stock split would result in an effective increase in the authorized number of shares of Common Stock available for issuance, which could, under certain circumstances, have anti-takeover implications.
Risks
- The company may not regain compliance with Nasdaq listing requirements despite the reverse stock split.
- The stock price may decline due to various factors, including future performance and general market conditions.
- The liquidity of the common stock may be negatively impacted by the reduced number of shares outstanding.
- The additional shares of Common Stock available for issuance could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or in our management.
Future Outlook
The company intends to appeal the delisting notice from Nasdaq and may implement the reverse stock split while awaiting the hearing date. The Board will determine the specific reverse stock split ratio based on its assessment of various factors.
Industry Context
Reverse stock splits are a relatively common strategy for companies facing delisting from exchanges due to low stock prices. The success of a reverse stock split in maintaining listing and improving stock performance varies widely depending on the company's underlying fundamentals and market conditions.
Comparison to Industry Standards
- Many companies in similar situations, such as those in the biotechnology and pharmaceutical sectors, have used reverse stock splits to regain compliance with exchange listing requirements.
- The effectiveness of a reverse stock split depends on the company's ability to improve its financial performance and investor confidence following the split.
- Companies like BioSpecifics Technologies Corp. and Delcath Systems, Inc. have undergone reverse stock splits in the past to maintain their Nasdaq listings, with varying degrees of success.
Stakeholder Impact
- Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same (except for fractional shares).
- Employees may experience uncertainty due to the potential delisting and reverse stock split.
- The company's ability to raise capital and pursue business development opportunities may be affected by its Nasdaq listing status.
Next Steps
- The company intends to file an appeal to the Nasdaq Hearing Panel.
- The Board will determine the specific reverse stock split ratio and the effective date.
- The company will implement the reverse stock split at least 20 days after mailing the information statement to shareholders.
- The company will monitor the stock price to ensure compliance with Nasdaq listing requirements.
Key Dates
| Date | Description |
|---|---|
| August 12, 2024 | Record Date for determining shareholders entitled to notice of the Written Consent and the date the Majority Shareholders adopted resolutions approving the Approval of Certificate of Incorporation Amendment for Split. |
| September 3, 2024 | Deadline for Elevai Labs Inc. to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule). |
| September 4, 2024 | Nasdaq sent a letter of deficiency stating that Elevai Labs Inc. had failed to regain compliance with the Bid Price Rule and its stock is subject to delisting. |
| September 5, 2024 | Date on or about when the Information Statement is first being mailed to shareholders. |
| September 5, 2024 | Date used for security ownership calculations. |
| September 6, 2024 | Date of the Board of Directors' order for the Information Statement. |
Keywords
reverse stock split, Nasdaq, delisting, common stock, listing requirements, shareholders, stock price, market capitalization, compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.